Revenue

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

AMC sells its Hycroft Mining stake to gold titan Eric Sprott for $24.1M, ending a curious diversification to double down on its core cinema business.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.

A junior miner's auditor and finance chief changes signal a calculated move to de-risk its path to becoming a major developer of a 'green' gold mine.

With shareholder approval secured, the HNI-Steelcase merger is set to create a $5.8B powerhouse. But can it deliver on its $120M synergy promise?

A 209kg opium seizure reveals how Canada's billion-dollar investment in AI and intelligence is disrupting sophisticated global drug smuggling networks.

As Virginia faces slowing growth, the business community presents a new decade-long economic plan to Governor-elect Spanberger. Can it deliver prosperity?

Ottawa's new protectionist policies for steel and lumber are more than a trade strategy; they're a massive public health intervention for at-risk communities.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

A Canadian firm's breakthrough promises to produce renewable natural gas at price parity with fossil fuels. Is this the key to unlocking a greener economy?

USA Pickleball's exclusive DUPR deal aims to unify the sport, but a single rating system brings both professional legitimacy and player controversy.

Following a strategic merger, the National Down Syndrome Society appoints six new leaders, signaling a new era of inclusive, research-driven advocacy.

Up to 60% of disability claims are denied, leaving sick Canadians in financial ruin. We explore the insurer tactics and the fight to reclaim benefits.

Empire State Realty Trust's latest dividend signals resilience. We explore how its modernized portfolio and NYC's market rebound create stability.

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

In a powerful move, Ashkenazy Acquisition Corp. acquires a major Chicago retail center, part of a $750M spree that defies market doomsayers.

The Dot Corp's new division signals a major shift in marketing logistics. Why are companies abandoning siloed vendors for a single source of truth?

Chile's state oil firm is using strong profits to buy back $150M in debt. Is this just smart accounting, or a move to fund its green hydrogen ambitions?